Mesoporous silica nanoparticles combined with AKR1C3 siRNA inhibited the growth of castration-resistant prostate cancer by suppressing androgen synthesis in vitro and in vivo

Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy

(2020) Yazhe Wang et al.   ACS Applied Materials & Interfaces

Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)

(2020) Yinxue Song et al.   BIOMEDICINE & PHARMACOTHERAPY

GRIM-19 over-expression represses the proliferation and invasion of orthotopically implanted hepatocarcinoma tumors associated with downregulation of Stat3 signaling

(2019) Dexia Kong et al.   BioScience Trends

Dioscin improves postmenopausal osteoporosis through inducing bone formation and inhibiting apoptosis in ovariectomized rats

(2019) Shan Wu et al.   BioScience Trends

Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances

(2018) Reema Narayan et al.   Pharmaceutics

Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook

(2016) Yuanhui Song et al.   International Journal of Nanomedicine

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer

(2016) Chengfei Liu et al.   MOLECULAR CANCER THERAPEUTICS

Mesoporous silica nanoparticles functionalized with folic acid/methionine for active targeted delivery of docetaxel

(2016) Pegah Khosraviyan et al.   OncoTargets and Therapy

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer

(2015) C. Liu et al.   CANCER RESEARCH

AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression

(2014) Yuantong Tian et al.   Diagnostic Pathology

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects

(2014) R Ferraldeschi et al.   ONCOGENE

Chitosan-Capped Mesoporous Silica Nanoparticles as pH-Responsive Nanocarriers for Controlled Drug Release

(2013) Xiaoxi Hu et al.   Chemistry-An Asian Journal

Steroidogenic Enzyme AKR1C3 Is a Novel Androgen Receptor-Selective Coactivator that Promotes Prostate Cancer Growth

(2013) M. Yepuru et al.   CLINICAL CANCER RESEARCH

AKR1C3 as a target in castrate resistant prostate cancer

(2013) Adegoke O. Adeniji et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

RNA-Based Therapeutics: Current Progress and Future Prospects

(2012) John C. Burnett et al.   CHEMISTRY & BIOLOGY

Activation of the Androgen Receptor by Intratumoral Bioconversion of Androstanediol to Dihydrotestosterone in Prostate Cancer

(2011) James L. Mohler et al.   CANCER RESEARCH

Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progressioan

(2010) Mikhail G Dozmorov et al.   BMC CANCER

Increased Expression of Androgen Receptor Sensitizes Prostate Cancer Cells to Low Levels of Androgens

(2009) K. K. Waltering et al.   CANCER RESEARCH

Androgen Levels Increase by Intratumoral De novo Steroidogenesis during Progression of Castration-Resistant Prostate Cancer

(2008) J. A. Locke et al.   CANCER RESEARCH